Recently, a new class of nitric-oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) is being studied as 'Safe NSAIDs' because of their gastric-sparing properties. As an extension of our novel disulfide linker technology, we have designed, synthesized and evaluated novel NO-releasing NSAID prodrugs such as NO-Aspirin (1b-d) and NO-Diclofenac (2b-c). Although the amide-containing derivative 1d did not show any bioavailability, the remaining compounds have shown fair to excellent pharmacokinetic, anti-inflammatory and gastric-sparing properties. Among them, however, the NO-Diclofenac (2b) has shown the most promising pharmacokinetic, anti-inflammatory and NO-releasing properties and protected rats from NSAID-induced gastric damage which could be attributable to the beneficial effects of NO released from these prodrugs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.07.142DOI Listing

Publication Analysis

Top Keywords

non-steroidal anti-inflammatory
8
anti-inflammatory drugs
8
gastric-sparing properties
8
pharmacokinetic anti-inflammatory
8
no-nsaids gastric-sparing
4
gastric-sparing nitric
4
nitric oxide-releasable
4
oxide-releasable prodrugs
4
prodrugs non-steroidal
4
anti-inflammatory
4

Similar Publications

Purpose: To compare the analgesic efficacy, adverse effects, and long-term functional outcomes of perioperative naproxen alone versus naproxen with pregabalin for treating pain in ankle fractures.

Methods: This study included 70 patients who underwent operative fixation of rotatory ankle fractures. Group A received naproxen 500 mg only, and Group B received naproxen 500 mg with pregabalin 75 mg 2-hour before surgery and 12 hourly for 14 days thereafter.

View Article and Find Full Text PDF

Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended to treat moderate-to-severe pain. Previous studies suggest that NSAIDs can suppress cellular proliferation and elevate apoptosis in different cancer cells. Ketorolac is an NSAID and can reduce the cancer cells' viability.

View Article and Find Full Text PDF

Hemorrhagic cholecystitis afflicted with glanzmann thrombasthenia patient.

J Family Med Prim Care

November 2024

Department of Basic Science College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

Article Synopsis
  • Hemorrhagic cholecystitis is a rare but serious condition that can occur if the gallbladder bursts, necessitating urgent medical intervention.
  • A 27-year-old man with Glanzmann's thrombasthenia visited the emergency department multiple times, initially presenting with ear and later chest pain, before being misdiagnosed and sent home.
  • Upon returning with abdominal symptoms, an ultrasound confirmed cholecystitis, leading to an emergency surgery that uncovered the hemorrhagic cholecystitis diagnosis.
View Article and Find Full Text PDF

Introduction: Fungi, including , may be a trigger or exacerbate psoriasis, especially in difficult to treat (DTT) areas, through the activation of IL-17/23 axis.

Methods: In this study, seventy patients with DDT psoriasis were enrolled to evaluate species and/or other opportunistic fungi colonization rate at baseline (T0) and the impact of apremilast on fungal load, clinical outcome, serum cytokine levels and biochemical serum profile of patients after 16, 24 and 52 weeks of treatment.

Results: In our population, 33 (47%) patients were colonized by spp.

View Article and Find Full Text PDF

Background: Bipartite medial cuneiform bone (BMC) is located at the Lisfranc joint of the midfoot, and it represents a rare variant involving two separate ossification centers in the medial cuneiform bone. Although BMC is typically asymptomatic, it can become clinically relevant under conditions of trauma or chronic stress, affecting foot stability.

Case Report: The current imaging report describes a 48-year-old female presenting with chronic dorsal midfoot pain, worsened by extended standing and ambulation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!